Global Cord Blood (NYSE:CO) Earns Strong-Buy Rating from Analysts at StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Global Cord Blood (NYSE:CO) in a note issued to investors on Saturday. The brokerage set a “strong-buy” rating on the medical research company’s stock.

Global Cord Blood Stock Performance

CO opened at $0.80 on Friday. Global Cord Blood has a 12-month low of $2.03 and a 12-month high of $5.50. The business’s fifty day simple moving average is $0.98 and its 200-day simple moving average is $1.26. The company has a market capitalization of $97.24 million, a price-to-earnings ratio of 1.25 and a beta of 0.16.

Global Cord Blood Company Profile

Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.